Substrate-reduction therapy enhances the benefits of bone marrow transplantation in young mice with globoid cell leukodystrophy

Pediatric Research

Volumn 51, Issue 1, 2002, Pages 40-47

  Biswas, S ^a   Levine, S M ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; GALACTOSYLCERAMIDASE; GLIAL FIBRILLARY ACIDIC PROTEIN; LECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BODY WEIGHT; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DEMYELINATION; GLOBOID CELL LEUKODYSTROPHY; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

EID: 0036134280     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/00006450-200201000-00009     Document Type: Article

References (52)

1. Cloning and expression of cDNA encoding human galactocerebrosidase, the enzyme deficient in globoid cell leukodystrophy
2. Globoid cell leukodystrophy: Additional deficiency of psychosine galactosidase
3. Inhibition of cytochrome c oxidase and hemolysis caused by lysosphingolipids
4. Phosphorylation of myelin basic protein in intact oligodendrocytes: Inhibition by galactosylsphingosine and cyclic AMP
5. Effect of psychosine on mitochondrial function
6. Gaucher disease of the Norrbottnian type (type III). Phenotypic manifestations
7. Diffuse gliosis of the cerebral white matter in a child
8. A new familial, infantile form of diffuse brain sclerosis
9. Krabbe disease: Genetic aspects and progress toward therapy
10. Molecular basis of late-life globoid cell leukodystrophy
11. Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy
12. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome
13. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation
14. Molecular heterogeneity of Krabbe disease
15. Late-onset Krabbe disease (globoid cell leukodystrophy): Clinical and biochemical features of 15 cases
16. Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: A Y-chromosome specific in situ hybridization study
17. Distribution and characterization of GFP(+) donor hematogenous cells in Twitcher mice after bone marrow transplantation
18. Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe's disease
19. Hereditary leucodystrophy in the mouse: The new mutant twitcher
20. The twitcher mouse: An alteration of the unmyelinated fibers in the PNS
21. The twitcher mouse: A model for Krabbe disease and for experimental therapies
22. Hematopoietic cell transplantation in murine globoid cell leukodystrophy (the twitcher mouse): Effects on levels of galactosylceramidase, psychosine, and galactocerebrosides
23. Effect of bone marrow transplantation on enzyme levels and clinical course in the neurologically affected twitcher mouse
24. Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice
25. Alleviation of neurologic symptoms after bone marrow transplantation in twitcher mice
26. Chemotherapy by slowing glucosphingolipid synthesis
27. Glycosyltransferases of rat brain that make cerebrosides: Substrate specificity, inhibitors, and abnormal products
28. Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain
29. Treating glucosphingolipid disorders by chemotherapy: Use of approved drugs and over-the-counter remedies
30. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin
31. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases
32. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
33. Inhibition of cerebroside synthesis in the brains of mice treated with L-cycloserine
34. Inhibition of sphingolipid synthesis by cycloserine in vitro and in vivo
35. The long-term administration of L-cycloserine to mice: Specific reduction of cerebroside level
36. Cycloserine-induced decrease of cerebroside in myelin
37. L-Cycloserine slows the clinical and pathological course in mice with globoid cell leukodystrophy (twitcher mice)
38. Biochemistry and neuropathology of mice doubly deficient in synthesis and degradation of galactosylceramide
39. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation
40. IL-6 deficiency allows for enhanced therapeutic value after bone marrow transplantation across a minor histocompatibility barrier in the twitcher (globoid cell leukodystrophy) mouse
41. Spacio-temporal progression of demyelination in twitcher mouse: With clinico-pathological correlation
42. Twitcher mice with only a single active galactosylceramide synthase gene exhibit clearly detectable but therapeutically minor phenotypic improvements
43. Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse
44. Hematopoietic cell transplantation after administration of high-dose busulfan in murine globoid cell leukodystrophy (the twitcher mouse)
45. The turnover of myelin in the adult rat
46. The turnover of myelin phospholipids in the adult and developing rat brain
47. The turnover of myelin phosphatidylcholine and sphingomyelin in the adult rat brain
48. The twitcher mouse. Central nervous system pathology after bone marrow transplantation
49. Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome
50. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III